Dr. Sander van Deventer joined uniQure as Chief Scientific Officer, General Manager, Amsterdam in August, 2017.
Dr. van Deventer was a co-founder of uniQure's predecessor Amsterdam Molecular Therapeutics (AMT) in 1998 and Board member since 2010.
Dr. van Deventer is currently Managing Partner at Forbion Capital partners and Professor of Translational Gastroenterology at Leiden University Medical Center. He also currently serves as member of the Board for Argos Therapeutics (Durham, USA), Hookipa (Vienna, Austria), Staten Biotechnology (Naarden, The Netherlands) and enGene (Montreal, Canada).
Dr. van Deventer is a trained internist and board-certified gastroenterologist. He received a Ph.D. from the University of Amsterdam, and became Director of the Laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995.